Bristol Myers' Arlo-cel Hits Primary Endpoint in Pivotal Multiple Myeloma Trial
BMY sits 58% above its 52-week low of $42.52.
Summary
Bristol Myers Squibb announced positive topline results from the registrational Phase 2 QUINTESSENTIAL trial of arlocabtagene autoleucel (arlo-cel), a potential first-in-class GPRC5D-directed CAR T therapy for quadruple-class exposed relapsed/refractory multiple myeloma. The study met its primary endpoint of overall response rate and key secondary endpoints including complete response rate, with a safety profile consistent with other CAR T therapies. This is the first disclosure of these data and supports a differentiated mechanism (GPRC5D) that remains effective after BCMA-targeted therapy, addressing a growing patient population with limited options. The company plans to present full results at an upcoming medical meeting and will likely pursue regulatory submission. This follows recent positive news for BMY's multiple myeloma franchise, including FDA acceptance of mezigdomide and accelerated approval of iberdomide, reinforcing its leadership in cell therapy.
At the time of this announcement, BMY was trading at $67.00 on NYSE in the Life Sciences sector, with a market capitalization of approximately $136.5B. The 52-week trading range was $42.52 to $68.64. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: BusinessWire.